Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the "Best of" Trial. by Stelmes, Jean-Jacques et al.
PERSPECTIVE
published: 22 October 2019
doi: 10.3389/fonc.2019.00999
Frontiers in Oncology | www.frontiersin.org 1 October 2019 | Volume 9 | Article 999
Edited by:
Remco De Bree,
University Medical Center
Utrecht, Netherlands
Reviewed by:
Edgar K. Selzer,
Medical University of Vienna, Austria
Sebastien Vergez,
Institut Universitaire du Cancer de
Toulouse Oncopole, France
*Correspondence:
Christian Simon
christian.simon@chuv.ch
Specialty section:
This article was submitted to
Head and Neck Cancer,
a section of the journal
Frontiers in Oncology
Received: 27 February 2019
Accepted: 17 September 2019
Published: 22 October 2019
Citation:
Stelmes J-J, Gregoire V, Poorten VV,
Golusiñski W, Szewczyk M, Jones T,
Ansarin M, Broglie MA, Giger R,
Klussmann JP, Evans M, Bourhis J,
Leemans CR, Spriano G, Dietz A,
Hunter K, Zimmermann F, Tinhofer I,
Patterson JM, Quaglini S,
Govaerts A-S, Fortpied C and
Simon C (2019) Organ Preservation
and Late Functional Outcome in
Oropharyngeal Carcinoma: Rationale
of EORTC 1420, the “Best of” Trial.
Front. Oncol. 9:999.
doi: 10.3389/fonc.2019.00999
Organ Preservation and Late
Functional Outcome in
Oropharyngeal Carcinoma: Rationale
of EORTC 1420, the “Best of” Trial
Jean-Jacques Stelmes 1, Vincent Gregoire 2, Vincent Vander Poorten 3,
Wojciech Golusiñski 4, Mateusz Szewczyk 4, Terry Jones 5, Mohssen Ansarin 6,
Martina A. Broglie 7, Roland Giger 8, Jens Peter Klussmann 9, Mererid Evans 10,
Jean Bourhis 11, C. René Leemans 12, Giuseppe Spriano 13, Andreas Dietz 14, Keith Hunter 15,
Frank Zimmermann 16, Ingeborg Tinhofer 17, Joanne M. Patterson 18, Silvana Quaglini 19,
Anne-Sophie Govaerts 20, Catherine Fortpied 20 and Christian Simon 21*
1Department of Radiation Oncology, University Hospital Zurich (USZ), Zurich, Switzerland, 2Department of Radiation
Oncology, Centre Léon Bérard, Lyon, France, 3 Section Head and Neck Oncology, Department of Oncology, KU Leuven,
Leuven, Belgium, 4Department of Head and Neck Surgery, The Greater Poland Cancer Centre, Poznan University of Medical
Sciences, Poznan´, Poland, 5 Liverpool Head and Neck Centre, University of Liverpool, Liverpool, United Kingdom, 6Division
of Otolaryngology Head and Neck Surgery, European Institute of Oncology, Milan, Italy, 7Department of Otolaryngology-Head
and Neck Surgery, University Hospital Zurich (USZ), Zurich, Switzerland, 8Department of Oto-Rhino-Laryngology, Head and
Neck Surgery, Bern University Hospital and University of Bern, Inselspital, Bern, Switzerland, 9Department of
Otolaryngology-Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany, 10 Velindre University
NHS Trust, Wales, United Kingdom, 11Department of Radiation Oncology, CHUV, Lausanne, Switzerland, 12Department of
Otolaryngology-Head and Neck Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centres, VU University,
Amsterdam, Netherlands, 13Department of Otolaryngology Head and Neck Surgery, Humanitas University Milan, Rozzano,
Italy, 14Department of Otolaryngology, Head and Neck Surgery, University Leipzig, Leipzig, Germany, 15 Academic Unit of Oral
Medicine, Pathology and Surgery, School of Clinical Dentistry, University of Sheffield, Sheffield, United Kingdom,
16Department of Radiation Oncology, University of Basel, Basel, Switzerland, 17Charité – Universitätsmedizin Berlin,
Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of
Radiooncology and Radiotherapy, Berlin, Germany, 18 Institute for Health and Society, Newcastle University, Newcastle upon
Tyne, United Kingdom, 19Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy,
20 EORTC Headquarters, Brussels, Belgium, 21 Service d’Oto-Rhino-Laryngologie – Chirurgie Cervico-Faciale, Centre
Hospitalier Universitaire Vaudois (CHUV), Université de Lausanne (UNIL), Lausanne, Switzerland
Dysphagia represents one of the most serious adverse events after curative-intent
treatments with a tremendous impact on quality of life in patients with head and neck
cancers. Novel surgical and radiation therapy techniques have been developed to better
preserve swallowing function, while not negatively influencing local control and/or overall
survival. This review focuses on the current literature of swallowing outcomes after
curative treatment strategies. Available results from recent studies relevant to this topic
are presented, demonstrating the potential role of new treatment modalities for early-
and intermediate-stage oropharyngeal cancers. Based on this, we present the rationale
and design of the currently active EORTC 1420 “Best of” trial, and highlight the potential
of this study to help prioritizing either surgery- or radiation-based treatment modalities
for the treatment of oropharyngeal cancer in the future.
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INTRODUCTION
The ideal treatment for any cancer should control the disease,
but inflict little, if any, toxicity. This paradigm is even more
important for cancers with a good prognosis, as patients who
survive for a longer period of time will have to deal with a full
spectrum of late-toxic events.
Head and neck cancers (HNC) and their treatment are
inevitably leading to dysphagia, which profoundly affects quality
of life (QOL). Dysphagia is the result of a dysfunction of
swallowing, one of the most complex physiological processes
coordinated by 30 different muscles and 6 cranial nerves (1, 2).
In early-stage HNC patients, among other stages, this is directly
linked to social and psychological problems (3).
Novel surgical- and radiotherapy (RT)-based strategies have
been developed within the past 10–20 years that allow for a more
targeted approach to the cure of early- and intermediate-stage
oropharyngeal cancers (OPSCC). In surgery, transoral surgical
endoscopic techniques (TOS) emerged, allowing for a reduction
of access trauma. This helped improve the functional recovery
of patients, particularly in terms of acute and late dysphagia (4).
For RT, the emergence of static and dynamic IntensityModulated
Radiation Therapy (IMRT, VMAT) allowed a better sparing of
healthy tissues surrounding the cancer and thus also led to better
functional recovery (4).
In this review, we address the rationale and design of EORTC
1420 “Best-of,” a trial comparing transoral surgery with intensity
modified radiation therapy (IMRT) and highlight how this
currently active phase III study could potentially change the
therapeutic landscape in this patient population and beyond for
HNC in general.
Although there is no prior prospective clinical trial that has
compared surgery vs. RT for early-stage and intermediate-stage
OPSCC in terms of survival, many retrospective studies have
shown equivalent disease-specific survival between these two
treatment modalities (DSS) rates (5–7). The largest and most
recently reported data from a multi-center US retrospective
study on approximately 400 patients with early and moderately
advanced OPSCC [89% OPSCC and 6% supraglottic cancers
(SGSCC)] treated with transoral robotic surgery (TORS)
reported a DSS of 94.5% at 2 years (6). Previous literature reviews
provide similar outcome results in terms of DSS at 2 years of
between 86 and 95% (8).
In an observational cohort study of 42 patients treated
between 1999 and 2001 for T1-2 N0 M0 oropharyngeal cancers,
patients were divided into those treated with TOS (+/– adjuvant
RT) and nonsurgical treatment with RT or CRT. Five-year DSS
was 69 vs. 60%, respectively (p = 0.22). The authors concluded
that surgical treatment allows for accurate staging and avoidance
of RT for patients with clearmargins; however, outcomes with the
two different regimens were similar (9). In a recent retrospective
analysis based on the National Cancer Database (NCDB), again
both treatment provided similar 5-year OS with 67% after
surgery-only and 65% after RT-only (10).
A meta-analysis by Morisod et al. included 729 patients with
early-stage OPSCC (T1-2 N0 M0). The authors demonstrated
a 5-year DSS of 90.4% in the RT group vs. 89.6% in the TOS
group, suggesting TOS to be equally effective in terms of tumor
control (11).
FUNCTIONAL OUTCOME OF OPSCC
PATIENTS
Recently, the results from the ORATOR trial (NCT01590355)
have been published, the first and only randomized comparison
of RT vs. TORS plus neck dissection for patients with OPSCC
(12). This trial was a multicenter, phase II randomized study
comparing primary RT (with or without chemotherapy) and
TORS with neck dissection (with or without adjuvant therapy) in
patients with T1 or T2, N0-N2 OPSCC. Patients were stratified
by p16 status. Primary endpoint was swallowing-related QOL
at 1 year using the M.D. Anderson dysphagia index (MDADI).
Sixty-eight patients were enrolled in this trial between 2012 and
2017. After amedian follow-up of 27months, total meanMDADI
scores were higher in the RT arm in comparison to TORS-based
treatment [86.9 (SD 11.4) vs. 80.1 (SD 13.0)]. Despite this, the
difference did not meet the pre-specified threshold (10 points)
for a clinically meaningful difference. Worth mentioning, in the
TORS plus neck dissection group, final staging was pT2 in 15
patients, pT3 in 4 patients, and pN2 in 17 patients. In total,
only 10 of 34 patients (29%) received surgery alone. Moreover,
tracheostomies were recommended. Two-thirds of the patients
received adjuvant treatment [24 of 34 (71%)]. Despite all this, the
TORS arm performed significantly poorer and even the post-hoc
analysis showed no difference between surgery-only and surgery
with adjuvant treatment consolidating the concern for TORS as
the primary treatment of this disease.
A cross-sectional study in locally advanced OPSCC compared
side effects of surgery plus post-operative RT vs. concurrent
chemoradiotherapy (CRT) based on the EORTC-QLQ-H&N35
questionnaire. The study group consisted of 57 patients. The
authors demonstrated that surgical patients described more
problems with swallowing (p = 0.042), social eating (p = 0.038),
and social contacts (p = 0.0002). Instead, patients treated with
concurrent CRT had more problems with teeth (p = 0.049), dry
mouth (p = 0.022), and sticky saliva (p = 0.044) (13). It is to be
speculated that one of the reasons for poor swallowing recovery
in the surgery group was the number of open trans-cervical or
combined transoral/trans-cervical procedures.
FUNCTIONAL OUTCOME AFTER RT
Xerostomia and dysphagia remain themost important side effects
following RT in HNC patients (14). In a UK prospective cohort
study of 167 patients treated with 3D-(C)RT, QOL and dysphagia
were evaluated with the MDADI and UWQOL (University
of Washington Head–Neck Quality of Life) questionnaires at
3, 6, and 12 months: All patients received three-dimensional
conformal treatment. There was a worsening of patient-reported
swallowing outcome by 18% from baseline at 3 months (mean
difference in the MDADI score = 14.5; p < 0.001). More
important, this worsening exceeded the minimally important
clinical difference (MICD) of 10 points, indicating a clinically
Frontiers in Oncology | www.frontiersin.org 2 October 2019 | Volume 9 | Article 999
Stelmes et al. Rationale of EORTC 1420 “Best of”
relevant worsening of swallowing for the patient. Furthermore,
little improvement could be observed from 3 to 12 months.
Another important finding was that dysphagia was significantly
less pronounced in patients treated with 50Gy compared to
63Gy, confirming the notion that not only volume but also
total dose plays a major role in swallowing dysfunction. In
addition, patients identified dysphagia and reduced/sticky saliva
in the UWQOL domains as the most devastating impairments.
In particular, dysphagia was highly correlated with long-term
functional and QOL outcomes (15).
Intensity modulated radiotherapy (IMRT) represents one
of the most important technology-driven advances in modern
oncology (16). Furthermore, no other group of cancer patients
has gained more by the introduction of IMRT, in terms of
reduction of long-term morbidity, than HNSCC patients. This
can, to some degree, be explained by the high number of organs at
risk in the head and neck region. Globally, IMRT allows delivery
of the necessary dose to the tumor in amuchmore conformal way
than was previously possible, by dividing the beam into multiple
small volumes (beamlets) of varying intensity (17).
In a randomized controlled trial, 94 patients with OPSCC
or hypopharyngeal cancer were treated between 2003 and 2007
with either 3D conformal RT (3D-CRT) or IMRT in the primary
setting. The primary endpoint was the proportion of patients
with xerostomia assessed by the LENT SOMA subjective side-
effect scale 1 year after treatment. The results showed a significant
reduction of xerostomia in the IMRT group, from 74% at 12
months in the 3D-CRT group to 38% in the IMRT group.
Furthermore, non-stimulated saliva flow from the contralateral
parotid was noted in 47% in the IMRT group compared to none
of the 25 patients in the 3DCRT group (p < 0.0001) (18). These
results have been underscored by the RTOG 0022 trial data, a
phase I/II study in patients with early-stage OPSCC treated with
moderately accelerated hypo-fractionated IMRT only: Patients
achieved high tumor control rates [2-year estimated loco-
regional-failure (LRF) rate 9%] and reduced salivary toxicity
compared with similar patients in previous studies (19).
Multiple studies have specifically evaluated the potential
benefit of IMRT in terms of functional outcomes and in particular
of swallowing function. A table summarizes a selection of
publications evaluating the impact of different RT techniques on
dysphagia (Table 1).
In addition to IMRT, new concepts have emerged to further
actively spare swallowing and salivary organs with the aim of
preserving swallowing function.
A prospective study by the Michigan group evaluated the
additional benefit of improved sparing of swallowing structures
such as the pharyngeal constrictors, the glottic and supraglottic
larynx in patients with stage III and IV OPSCC treated with
primary chemo-IMRT: In order to achieve this, the authors
defined clear dosimetric goals for these structures (Dmax <
50Gy). Additionally, the medial retropharyngeal nodes were not
included in the elective target volumes and the additional margin
from the microscopic extension to the planning target volume
was minimized (0.3 cm) (27): Overall, 73 patients were treated
with a median follow-up of 36 months. The primary endpoint
was patient-reported dysphagia assessed by the Eating Domain
of the Head and Neck Quality of Life questionnaire (HNQOL)
and the UWQOL. At 1 year, observer-rated dysphagia was absent
or minimal; however, patient-reported scores worsened by 10
(UWQOL) and 13 (HNQOL) points, respectively. Three-year
DFS was 88%, which is similar to standard IMRT treatments (21).
Pooled data from two prospective cohort studies, with a
median follow-up of 6.5 years, in which patients were treated with
swallowing and salivary organ-sparing IMRT, reported stable or
improved HRQOL in comparison to prior treatment (28).
Despite the nowadays standard use of IMRT in this patient
group, RT still has a significant impact on swallowing-related
QOL parameters: In a prospective cohort study of 62 patients
diagnosed with HNSCC treated with IMRT or chemo-IMRT,
Roe et al. showed a decrease of 20.8 points in swallowing
performance using the MDADI from baseline to 3 months
after treatment. A statistically significant improvement could be
observed between 3 and 12 months (15.7 points from baseline,
p= 0.04) (23).
In another retrospective trial of highly selected patients
with low to intermediate risk OPSCC who were treated with
laryngeal/esophageal inlet dose-optimized IMRT, a decrease of
15 points in the MDADI scale was observed at 6 months. A
statistically significant improvement was noticed at 24 months (p
= 0.02) in comparison to baseline. This suggested that patients
with OPSCC treated with esophageal inlet dose optimized IMRT
are highly likely to report recovery of acceptable swallowing
function on long-term follow-up (25).
Finally, the MD Anderson Head and Neck Cancer
Symptom Working Group analyzed, in a cohort of 300
patients treated with CRT between 2002 and 2011, the rate of
chronic radiation-induced dysphagia (RAD) at >12 months
post-IMRT. RAD was defined as (1) aspiration/stricture at
video-fluoroscopy/endoscopy, (2) gastrostomy tube, and/or (3)
aspiration pneumonia. In total, they found a rate of 11% chronic
RAD at 12 months. Interestingly, age and volume receiving more
than 69Gy were the most predictive covariates.
FUNCTIONAL OUTCOME AFTER
TRANSORAL SURGERY
Minimally invasive techniques, such as transoral laser
microsurgery (TLM) and TORS, have emerged within the
past two decades. The major aim of these novel strategies is to
reduce treatment-related morbidity while preserving excellent
oncological control. Swallowing function has been evaluated
after TLM and TORS in several studies (Table 2) and overall
outcomes have been promising.
A prospective study from the Mayo Clinic recruited 45
patients with OPSCC for TORS-based treatment. Swallowing
function was assessed by the Functional Outcome Swallowing
Scale (FOSS), an observer rated dysphagia outcome scale: All
patients who were treated with TORS and neck dissection only
and with a baseline score of 0 had a FOSS score of 0 at 4 weeks
after surgery, whereas patients after adjuvant CRT were found
to have FOSS scores of more than 2 at 3 months after finishing
treatment (30).
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TABLE 1 | Selected studies on dysphagia outcomes following primary radiotherapy with IMRT.
References Technique Combined
treatments (%)
Stage (%) Study type No.
patients
FU
(months)
Dysphagia outcomes
Anand et al. (20) IMRT RT alone: 29
CRT: 47
PORT:27
Stage III-IV:
77.3
Pooled analysis 62 19 Chronic dysphagia based on
the CTC grading Version 3.0
at 6 months
Grade I: 10.5%
Grade II: 12.3%
No Grade III
Feng et al. (21) SW IMRT CRT: 100 Stage III-IV:
100
Prospective cohort
study
73 36 UWQOL* & HNQOL*
At baseline: 10 & 8, at 24
months: 22 & 17
Schwartz et al.
(22)
Split-field IMRT
with laryngeal
shielding
Weekly induction
CT followed by
CRT in 42
RT alone: 58
Stage IV:
100
Phase II trial 48 24 MDADI
At baseline: 89.1
at 24 months: 82.4
No difference between CRT and
RT-only treated patients.
Nutting et al. (18) IMRT vs. 3D-CRT RT alone: 68 or 83
PORT: 17 or 32
NeoadjCT:40 or 43
Stage
III-IV-68 or
83
Phase III RCT 94 44 LENT SOMA late side-effects:
Dysphagia grade ≥3
At 12 months:
IMRT: 9%
3D CRT: 5%
At 24 months, no difference
between non-xerostomia late
toxicities between two groups
Roe et al. (23) PS IMRT RT alone: 21
CRT: 7
Induction CT +
CRT: 72
Stage III-IV:
92
Pooled analysis 62 12 MDADI
At baseline: 86.9
At 3 months: 66.1
At 12 months: 71.3
Mazzola et al. (24) IMRT CRT: 54%
PORT: 29%
Stage III-IV:
68
Pooled analysis 56 12 EORTC/RTOG scoring criteria
Chronic dysphagia at
12 months
Grade I: 91%
Grade II: 9%
Goepfert et al. (25) Split-field IMRT
with laryngeal
shielding
Induction CT.
+concurrent CT:
28%
Induction CT: 43%
Concurrent
CT: 57%
Stage III-IV:
100%
Pooled analysis 46 24 MDADI
At baseline: 90
At 6 months: 74.6
At 12 months: 78.5
At 24 months: 83.1
15% had a depressed score by
at least 20 points at 24 month
MD Anderson
Head and Neck
Cancer Symptom
Working Group
(26)
Split-field
IMRT/whole field
CRT T1-T4 N0
M0
Pooled analysis 300 48 Chronic RAD: 11%
PS, Parotid-sparing; SW, Swallowing-sparing; CT, Chemotherapy; CRT, combined chemoradiotherapy; RAD, radiation induced dysphagia. *Scores are in a scale of 0 to 100; higher
scores denote worse symptoms.
Another prospective case–control study was done by the
Mount Sinai School of Medicine, New York: They included
30 patients with mostly stage III–IV OPSCC (7th AJCC
classification) treated with TORS and adjuvant therapy.
Subjective and objective functional outcomes were measured
with the Performance Status Scale for Head and Neck Patients
(PSS-HN) and the Functional Oral Intake Score (FOIS). After a
median follow up of 14.8 months, they showed better functional
outcome with less eating- and diet-related changes in comparison
to controls treated with definitive CRT at 2 weeks (5.5 vs. 3.3;
p < 0.001). However, at 3, 6, 9, and 12 months, there were no
significant differences (31).
Sinclair et al. included 42 patients with T1 or T2 OPSCC in
a study aiming to evaluate based on the MDADI score patient
perceived swallowing function after TORS+/– RT or CRT: After
a median follow-up of 13.6 months, the meanMDADI score after
TORS was 74.3, which was comparable to that of patients treated
with CRT in other studies (23, 32, 38).
The group from Kansas led a prospective non-randomized
trial in patients with stage III or IV (7th AJCC classification)
OPSCC and SGSCC treated by either TORS with adjuvant RT
or definitive CRT. Primary endpoint was swallowing function
based on the MDADI score. At a mean follow-up of 14 months,
they found a significantly better swallowing MDADI outcome
compared to primary CRT at 12 months (78 vs. 60; p = 0.006)
with a return to baseline in the surgery arm. In comparison, in
the CRT group, a gradual improvement to 60 was made, but no
return to baseline (34).
In another study by Chen et al. a matched pair analysis
in patients with stage I–IV tonsils and base of tongue
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TABLE 2 | Dysphagia outcomes of trans-oral surgical (TOS) approaches for oropharyngeal squamous cell carcinoma (OPSCC).
References Surgical
procedure
Stage (%) Combined
treatments
(%)
Study type No.
patients
FU
(months)
Dysphagia outcomes
Iseli et al. (29) TORS T1:35, T2:44
Stage III-IV: n/a
Neoadjuvant
RT:22
PORT:41
POCRT: 31
Prospective cohort 54 13 Mean MDADI score declined
from 75 to 65 at 2 months
Moore et al. (30) TORS T1:33, T2:40
Stage III-IV: 86
PORT: 18
POCRT: 56
Prospective case
study
45 12.3 FOSS score
In case of TORS only, FOSS
score returned to 0 at 4 weeks
Genden et al. (31) TORS T1:53, T2:43
Stage III-IV:73
PORT: 10
POCRT: 27
Prospective case
control study
30 14.8 FOIS score*
returned to baseline at 12
months in the TORS-only group
Sinclair et al. (32) TORS T1:45, T2:55
Stage III: 76
No Stage IV
PORT: 45
CRT: 31
Prospective case
series
42 17 MDADI score
At baseline: 82 After
median FU:74
Moore et al. (33) TORS T1:46, T2:39
Stage III-IV: 90
PORT: 21
POCRT: 62
Prospective study 66 34 95.5% of patients maintain
nutrition without feeding tube
More et al. (34) TORS T1:30, T2:35
Stage III-IV:100
PORT: 40
POCRT:60
Prospective
comparative study
20 14 MDADI score returned to
baseline (78 points) in the TORS
group
Chen et al. (35) TORS/TLM T1:52, T2:39
83>N1
PORT: 84
POCRT: 16
Retrospective
matched pair
analysis
31 20 UW-QOL sore at 1 year 91.5
vs. 72.1 in patients treated with
TOS +adj. treatment
Sethia et al. (36) TORS T1: 62 T2:38
46 > N1
TORS
alone:12
PORT: 28
POCRT:60
Prospective cohort
study
111 35 HNCI eating domain score for
TORS alone was higher than for
adjuvant (C)RT at 3 months. (p <
0.01)
Morisod et al. (37) TORS 19 T1/T2N0
10
T1/T3N1-2B
Stage III-IV: 31
PORT: 28
CRT: 3
Prospective cohort
study
29 20 In the TORS only group: 67%
with stable or improved FOSS
score
*Mean FOIS: Mean Functional Oral Intake Score, PORT: Post-operative RT; POCRT: Post-operative CRT; TLM: Trans-oral laser-microsurgery.
tumors (7th AJCC classification) was performed. They evaluated
functional outcomes after TOS followed by risk-stratified
adjuvant treatment and primary CRT. Sixteen patients were
treated with TLM and 15 patients were treated with TORS.
The endpoint was QOL at 1 year based on the UWQOL score:
Subjective reporting of swallowing was better in the TOS with
adjuvant RT group in comparison to the CRT group at 1 year
(91.5 vs. 72.1; p= 0.01) (35).
The head and neck group from Ohio, USA, evaluated the
impact of adjuvant treatment after TORS on QOL in 111 patients
treated for OPSCC from 2005 to 2015. With a mean follow-up
of 35 months, based on the Head and Neck Cancer Inventory
(HNCI), TORS alone reported significantly higher eating scores
than after adjuvant RT or CRT at 3 and 6 months (p < 0.01) (36).
In a single institutional prospective cohort study on patients
with T1-2 N0-2b OPSCC, of which approximately 50% were
treated for secondary oropharyngeal primaries, the percentage of
patients with low FOSS scores (FOSS 0-2) did not significantly
change after TORS-based treatment (89 vs. 88.5%), indicating
low dysphagia rates after TORS, even in patients with previous
HNC treatments (37).
Finally, a systematic review of 11 studies (190 patients) in
early-stage OPSCC treated with TORS revealed a 5% incidence
of late gastrostomy tube dependence at more than 12 months
follow-up. In most studies, a near-complete recovery was
documented with changes smaller than the “minimally important
clinical difference” (7, 39).
DESIGN OF THE EORTC 1420 “BEST OF”
TRIAL
The EORTC 1420 “Best of” trial is an ongoing open-label
phase III prospective randomized trial assessing the “best of”
surgery compared to the “best of” RT initially in patients
with T1-2 N0 OPSCCs. This was recently amended to also
include T1-2 N0-1 OPSCC, SGSCC, and T1 N0 hypopharyngeal
squamous cell carcinoma that are p16 positive and p16
negative. The main objective of the study is to assess and
compare patient-reported swallowing function based on the
validated MDADI composite score over the first year after
randomization between TOS and IMRT (40, 41). Key secondary
endpoints are common oncological endpoints as well as
functional and HRQOL measures based on the PSS-HN, 100ml
swallow test, feeding tube use, and the EORTC QLQ-C30
and HN43.
Frontiers in Oncology | www.frontiersin.org 5 October 2019 | Volume 9 | Article 999
Stelmes et al. Rationale of EORTC 1420 “Best of”
Besides this main objective related to patient-reported
swallowing outcome comparing two treatment techniques, a
second objective is to identify the most optimal treatment for
early-stage HNSCCs in general that are amenable to single-
modality treatment. This certainly excludes tumor sites where
no controversy exists (i.e., oral cavity, nasopharynx). Finally,
EORTC 1420 is equipped with a translational research program
that attempts to run large-scale proteomics analysis on the
saliva of patients, in order to develop biomarkers allowing for
the prediction of functional recovery after one or the other
treatment. This objective may even be the most important
given that being able to predict functional recovery after various
treatments based on a biomarker prior treatment would solve the
entire controversy.
A total number of 170 patients (85 patients in each arm)
will be recruited to this study. Stratification factors are tumor
localization, N-stage,MDADI at baseline, and country. After a 1:1
randomization into TOS or IMRT, patients are followed at four
separate time points for patient-reported swallowing outcome in
order to assess the evolution of swallowing recovery with each
treatment technique.
In the TOS arm, any transoral technique (i.e., TLM, TORS,
etc.) can be used. Of importance is a quality assurance program
allowing for harmonization of techniques at a very high quality
level (42). In order to avoid post-operative RT in the surgery arm,
a re-resection policy was added to the protocol, requiring the
surgeon to revise a positive or close margin unless refused by the
patient. Also, tracheostomies are not in general recommended,
helping with the recovery of swallowing. In comparison to
the ORATOR protocol, the surgical procedures outlined in the
EORTC 1420 protocol are less invasive and allow other well-
established techniques such as TLM also to be performed.
For the IMRT arm, clinical target volumes for the
primary tumor and nodes as well as the swallowing
structures are contoured according to international guidelines
(43, 44) and strict dose constraints are defined concerning
relevant swallowing structures based on current literature
(22, 26, 27, 45, 46). Additionally, in order to reduce protocol
deviations, an extensive patient-specific quality assurance
program was implemented.
DISCUSSION
Patients recruited for EORTC 1420 “Best-of” will be randomized
between two currently “state of the art” treatments in their
respective field. The TOS arm offers a way of reducing toxicity by
accessing the tumor through themouth and removing the disease
via minimally invasive techniques using either a robotic system
or a laser. Clearly defined quality assurance guidelines and an
accreditation process for surgeons assure state-of-the-art conduct
of the operations and comparability of interventions (42).
The RT arm not only consists of a mandatory IMRT
technique with reducing dose to the contralateral parotid
gland, as it is used currently in most hospitals today, but
also contains defined dose constraints to different swallowing
organs that are needed to be contoured separately. Furthermore,
a strict quality-assurance program has been put in place in
order to guarantee optimal execution as it has been shown
that deviation from clinical protocol can have an impact
on clinical outcome (47).
As reported, the recently published ORATOR trial
was a phase II study, which compared RT-based and
TORS-based treatment in OPSCC in terms of swallowing
function at 1 year. Notwithstanding the similarities between
BEST-OF and ORATOR in light of study design, patient
selection, and primary endpoint, some differences need to
be mentioned:
1. In BEST-OF, not only OPSCC tumors are included, but
also supraglottic and T1 N0 hypopharyngeal carcinomas.
In addition, patients are stratified according to tumor
localization. It was also one of the conclusions from the
ORATOR trial that maybe certain subsites (tonsil or base of
tongue) or T-stages could help select the best treatment option
in the future.
2. Only N1 disease is allowed in BEST-OF as compared to a
maximum lymph node dimension of 4 cm in any plane, on
either side of the neck in the ORATOR trial (N2 disease). This
is potentially relevant as in ORATOR, 72% (n = 23) received
concurrent CRT in the RT arm and 24% (n= 8) adjuvant CRT
in the TORS arm.
3. In ORATOR, only TORS was allowed; however, in BEST-OF,
TLM and conventional transoral surgery are also permitted.
4. BEST-OF runs with an integrated quality program for surgery
consisting of a credentialing part and the follow-up on various
process and outcome indicators. The procedures in BEST-OF
seem less invasive andmore consistent with current European
standards of transoral organ preservation surgery, i.e., no
mandatory tracheostomy, possibility of margin revision, and
precautions to avoid resecting T3-disease.
In conclusion, BEST-OF is a phase III randomized trial, which
compares two different techniques (IMRT vs. TOS) in earlier
stages for multiple subsites as opposed to ORATOR, a phase II
trial, which compared two different multi-disciplinary treatment
strategies in more advanced disease and only for OPSCC.
Despite an abundance of published literature on acute
and late dysphagia after RT- or TOS-based treatments, it
is challenging to make unequivocal conclusions as to what
treatment should be prioritized, due to a high number of
methodological variations and the non-randomized nature of
most comparisons.
In addition, due to the high complexity of the impairment,
many cofounders exist: age, dental status, pretreatment
dysphagia, gender, location, and tumor volume, to name
a few (48). Since both novel surgical and radiation
techniques appear to offer equivalent efficacy in terms
of tumor control, it is essential to evaluate which one
would be superior in preserving function. Therefore,
only a randomized phase III design can elucidate which
treatment is best in which situation by properly evaluating
the respective benefits and disadvantages of these treatments
and highlight which one of the modalities will provide better
functional outcome.
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Surgery and RT still represent the backbone of curative
treatment for OPSCC (49). It would be ideal if such interventions
would come with limited or no morbidity, so that patients, if
requiring multi-modality treatment, could either move on to
adjuvant or receive additional treatments without any sequels
from their primary treatment. Therefore, the results from this
study are of major value as they help to define this backbone of
treatment that should be used in the future in combination with
additional, i.e., systemic therapies in advanced disease or novel
de-intensification regimens.
CONCLUSION
The question addressed in “BEST-OF” is timely and of interest to
the community as it responds to a major public health problem.
Dysphagia is a key symptom related to many comorbidities
like poor nutrition, dehydration, aspiration pneumonia, feeding
tube dependence, depression, and isolation (50, 51). Chronic
aspiration is a particularly serious and often underestimated side
effect among OPSCC patients undergoing CRT, with a reported
rate of 7.6% (52). Within a growing and aging world population
with an increase of human papillomavirus-driven pharyngeal
tumors, dysphagia will become of even more importance in the
coming years. Therefore, this trial still responds to an urgent
unmet need to devise efficient dysphagia-sparing treatment
strategies in a randomized and pragmatic design (2, 53, 54).
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